Upper gastrointestinal motility. Part I--The pathophysiologic approach to the management of reflux esophagitis.
D000863:Antacids / Q000627:therapeutic use; D001626:Bethanechol Compounds / Q000627:therapeutic use; D002229:Carbenoxolone / Q000627:therapeutic use; D004942:Esophagitis, Peptic / Q000503:physiopathology / Q000628:therapy*; D004943:Esophagogastric Junction / Q000503:physiopathology; D005746:Gastric Emptying; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000209:etiology; D005769:Gastrointestinal Motility; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D011187:Posture
D000863:Antacids; D001626:Bethanechol Compounds; D006635:Histamine H2 Antagonists; D008787:Metoclopramide; D002229:Carbenoxolone